Payment overview · 2025
General Payments
$279.15
4 reported records · 4 companies
Healthcare provider profile · identity verified
Mark R Fox, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FINDLAY, OH · NPI 1831147560
Verified facts
What the public records show
CMS Open Payments records show Mark R Fox, M.D. received $279.15 in general payments during 2025 across 4 reported records.
Axsome Therapeutics, Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 44.8% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $103.15 | 37.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.00 | 12.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.00 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.15 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $103.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 276 |
| Lisinopril | Lisinopril | 682 | 186 |
| Omeprazole | Omeprazole | 661 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 624 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 152 |
| Metoprolol Tartrate | Metoprolol Tartrate | 470 | 130 |
| Simvastatin | Simvastatin | 470 | 127 |
| Metformin Hcl | Metformin Hcl | 383 | 107 |
| Losartan Potassium | Losartan Potassium | 298 | 85 |
| Eliquis | Apixaban | 288 | 54 |
| Alprazolam | Alprazolam | 259 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 63 |
| Gabapentin | Gabapentin | 224 | 47 |
| Furosemide | Furosemide | 218 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 58 |
| Potassium Chloride | Potassium Chloride | 198 | 54 |
| Glipizide | Glipizide | 162 | 38 |
| Allopurinol | Allopurinol | 158 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 150 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 149 | 41 |
| Alendronate Sodium | Alendronate Sodium | 143 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 28 |
| Sertraline Hcl | Sertraline Hcl | 137 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 30 |
| Meclizine Hcl | Meclizine Hcl | 121 | 59 |
| Azithromycin | Azithromycin | 120 | 86 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 26 |
| Meloxicam | Meloxicam | 119 | 29 |
| Ozempic | Semaglutide | 115 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 28 |
| Tramadol Hcl | Tramadol Hcl | 112 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 110 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 37 |
| Trazodone Hcl | Trazodone Hcl | 107 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 22 |
| Prednisone | Prednisone | 102 | 30 |
| Memantine Hcl | Memantine Hcl | 95 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 92 | 23 |
| Carvedilol | Carvedilol | 91 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 27 |
| Jardiance | Empagliflozin | 89 | 23 |
| Synthroid | Levothyroxine Sodium | 89 | 29 |
| Warfarin Sodium | Warfarin Sodium | 89 | 25 |
| Buspirone Hcl | Buspirone Hcl | 87 | 13 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 22 |
| Spironolactone | Spironolactone | 79 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 14 |
| Bumetanide | Bumetanide | 75 | 26 |
| Bupropion Xl | Bupropion Hcl | 75 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 16 |
| Clonidine Hcl | Clonidine Hcl | 71 | 16 |
| Cephalexin | Cephalexin | 70 | 53 |
| Famotidine | Famotidine | 68 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 11 |
| Nifedipine Er | Nifedipine | 61 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 14 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 18 |
| Midodrine Hcl | Midodrine Hcl | 57 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 26 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Methylprednisolone | Methylprednisolone | 52 | 44 |
| Finasteride | Finasteride | 51 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Glipizide Er | Glipizide | 51 | 12 |
| Baclofen | Baclofen | 46 | 13 |
| Gemfibrozil | Gemfibrozil | 46 | 11 |
| Donepezil Hcl | Donepezil Hcl | 45 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Atenolol | Atenolol | 40 | 13 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Restasis | Cyclosporine | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Montelukast Sodium | Montelukast Sodium | 36 | 12 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Nystatin | Nystatin | 31 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 16 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Torsemide | Torsemide | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.15 · 4 records | Axsome Therapeutics, Inc. | AREXVY, NEFFY, Symbravo, TRELEGY ELLIPTA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error